Dinh NH, et al. - Researchers analyzed healthy control participants as well as patients with end-stage renal disease (ESRD) in this retrospective study to assess the validity of reticulocyte hemoglobin content (CHr) and percentage of hypochromic red blood cells (%Hypo) in screening iron-deficiency anemia (IDA) in ESRD patients, as well as to compare their performance with screening IDA in non-ESRD patients. It was noted that IDA identification in ESRD patients was more complicated, because in ESRD patients vs non ESRD group, there was a lower screening performance of CHr and %Hypo in predicting IDA, but was still reasonable with AUC = 0.748 and 0.740, respectively. Overall, CHr and %Hypo seemed to represent beneficial tools for screening IDA in both non ESRD and ESRD patients. These two markers have low cost and are accessible, and this support their utility as effective screening instruments in clinical practice.